ArticleO&G open2026
Comparative Effectiveness of Empiric Antibiotics for Uncomplicated Urinary Tract Infection in Postmenopausal Women.
Article in O&G open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the effectiveness of antibiotic regimens for acute uncomplicated urinary tract infection (UTI) in postmenopausal women using real-world clinical data.
methodsWe conducted a retrospective cohort study in the TriNetX database of women aged 40 years or older with menopausal or postmenopausal status who developed acute uncomplicated cystitis or UTI between March 2006 and March 2026. Patients were stratified by initial antibiotic therapy of nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX), or fosfomycin. The primary outcome was a composite measure of treatment failure within 7 days of treatment initiation, including antibiotic escalation, pyelonephritis, bacteremia, sepsis, hospitalization, critical care services, and mortality. Propensity score matching was used to balance demographics, laboratory values, comorbidities, and prior gynecological procedures. Outcomes were compared between matched groups with a two-sided
resultsA total of 236,927 postmenopausal women initiating antibiotics to treat uncomplicated UTI were identified (nitrofurantoin n=152,793; TMP-SMX n=80,815; and fosfomycin n=3,319). After matching, TMP-SMX was associated with a higher risk of composite treatment failure compared with nitrofurantoin (10.2% vs 8.0%, relative risk ratio [RR] 1.28, 95% CI, 1.23-1.32). In addition, TMP-SMX was associated with higher rates of antibiotic escalation, pyelonephritis, bacteremia, sepsis, hospitalization, critical care services, and mortality. Compared with fosfomycin, TMP-SMX was associated with a higher risk of composite treatment failure (13.3% vs 9.6%, RR 1.39, 95% CI, 1.21-1.59), as well as higher rates of sepsis, hospitalization, and critical care services. Nitrofurantoin and fosfomycin had similar rates of composite treatment failure (9.0% vs 9.6%, RR 0.93, 95% CI, 0.80-1.09), although hospitalization was less frequent with nitrofurantoin (1.8% vs 3.0%, RR 0.60, 95% CI, 0.44-0.82).
conclusionAmong postmenopausal women with acute uncomplicated UTI, treatment with TMP-SMX was associated with higher rates of adverse outcomes and serious infectious complications compared with nitrofurantoin and fosfomycin. Nitrofurantoin and fosfomycin demonstrated similar short-term outcomes. These findings support the need for postmenopausal-specific evidence to inform empiric UTI treatment selection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.